Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 250 for your search:
Drug:
etoposide
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
15 to 65
Sponsor:
Other
Protocol IDs:
GMALL01
, NCT00198991
2.
Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
15 to 65
Sponsor:
Other
Protocol IDs:
GMALL03
, NCT00199004
3.
Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-Grade Lymphoma in Adults
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
Over 15
Sponsor:
Other
Protocol IDs:
GMALL05
, NCT00199082
4.
Efficacy of G-CSF-Priming in Elderly AML Patients
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
Over 60
Sponsor:
Other
Protocol IDs:
AML-elderly 01/99 Trial
, NCT00199147
5.
Study Treatment to Low Risk ALL
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
15 and under
Sponsor:
Other
Protocol IDs:
LAL-BR/2001
, NCT00526175
6.
German Multicenter Trial for the Treatment of Newly Diagnosed T-Lymphoblastic Lymphoma in Adults
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
15 to 65
Sponsor:
Other
Protocol IDs:
GMALL04
, NCT00199017
7.
Phase II/III Randomized Study of Bleomycin, Cisplatin, and Etoposide (BEP) Versus Bleomycin, Cisplatin, Etoposide, and Paclitaxel (T-BEP) in Men With Intermediate Prognosis Germ Cell Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
16 to 50
Sponsor:
Other
Protocol IDs:
EORTC-30983
, NCT00003643
8.
Phase II/III Study of Standard and Novel Conditioning Therapy Followed By Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia or Hematologic Malignancy
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
4 to 70
Sponsor:
Other
Protocol IDs:
RPCI-RP-9815
, NCI-V99-1527, NCT00003816, RP 98-15
9.
Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
UARK 2003-26
, NCT00090493
10.
Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 to 60
Sponsor:
Other
Protocol IDs:
AMLSG07-04
, NCT00151242
11.
A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
Haema CBF SCLC UK/AS 01
, NCT00168896
12.
Phase II/III Study of Disease-Specific High-Dose Conditioning Regimens Followed by Autologous Stem Cell Transplantation (Single or Tandem) in Patients With Hematologic Malignancies or Solid Tumors
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
4 and over
Sponsor:
NCI
Protocol IDs:
RPCI-I-72806
, I 72806, NCT00536601
13.
Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma
Phase:
Phase III, Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
2006-0374
, NCT00539500
14.
Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
0 to 30
Sponsor:
Other
Protocol IDs:
EUDRACT 2005-002618-40
, BfArM-4030755, EC-105/05, DKS 2006.01, NCT00749723
15.
Phase III Study of Early High-Dose Chemoradiotherapy and Autologous Peripheral Blood Stem Cell Transplantation Versus Conventional Dose Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Intermediate- or High-Grade Non-Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
15 to 65
Sponsor:
NCI
Protocol IDs:
SWOG-S9704
, CAN-NCIC-LY11, CALGB-59903, ECOG-S9704, S9704, NCT00004031, LY11
16.
Phase III Randomized Study of Dexamethasone Versus Prednisolone During Induction Therapy and Prolonged Versus Conventional Duration Asparaginase During Consolidation and Late Intensification Therapy in Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 18
Sponsor:
Other
Protocol IDs:
EORTC-58951
, NCT00003728
17.
Phase III Randomized Study of High-Dose Versus Standard-Dose Cytarabine During Induction and Interleukin-2 Following Intensive Consolidation and Autologous Peripheral Blood Stem Cell Transplantation in Patients With Acute Myeloid Leukemia
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
15 to 60
Sponsor:
Other
Protocol IDs:
EORTC-06991
, NCT00004128, GIMEMA-EORTC-06991
18.
Phase III Randomized Study of Induction and Maintenance Chemotherapy Regimens With Different Doses and Schedules of Methotrexate From the Berlin-Frankfurt-Munster-K2 Protocol With or Without Vinblastine in Children With Anaplastic Large Cell Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 22
Sponsor:
Other
Protocol IDs:
FRE-IGR-ALCL99
, EU-20031, NHL2000/06, NCT00006455
19.
Phase III Randomized Study of Sequential Chemotherapy With or Without Rituximab Followed By Ablative Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation in Patients With Relapsed, CD20 Positive, Aggressive B-Cell Non-Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
CKTO-2000-06
, HOVON-44, HOVON-44/CKVO-2000-06, EU-20042, ISRCTN95614846, NCT00012051
20.
Phase III Randomized Study of Standard Induction Chemotherapy Comprising Vincristine, Dactinomycin, Ifosfamide, and Etoposide Followed By Consolidation Chemotherapy Comprising Vincristine, Dactinomycin, and Ifosfamide Versus High-Dose Busulfan and Melphalan Followed By Autologous Peripheral Blood Stem Cell Support With or Without Radiotherapy and/or Surgery in Patients With Tumor of the Ewing's Family
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 50
Sponsor:
NCI, Other
Protocol IDs:
EURO-EWING-INTERGROUP-EE99
, EBMT-INTERGROUP-EE99, EORTC-62981, GPOH-AUSTRIA-INTERGROUP-EE99, GPOH-GERMANY-INTERGROUP-EE99, SFOP-INTERGROUP-EE99, SWS-SAKK-INTERGROUP-EE99, CCLG-INTERGROUP-EE99, COG-AEWS0331, NCT00020566, AEWS0331
21.
Phase III Randomized Study of Response-Based Chemotherapy With Doxorubicin, Bleomycin, Vincristine, Etoposide, Prednisone, and Cyclophosphamide With or Without Dexamethasone, Etoposide, Cytarabine, Cisplatin, and/or Radiotherapy in Children With Newly Diagnosed Intermediate-Risk Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
NCI
Protocol IDs:
COG-AHOD0031
, NCT00025259, AHOD0031
22.
Phase III Randomized Study of Induction Chemotherapy With or Without Filgrastim (G-CSF) Followed By Surgery, Myeloablative Therapy, and Radiotherapy With Isotretinoin With or Without Monoclonal Antibody Ch14.18 in Patients With High-Risk Neuroblastoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
1 to 20 at diagnosis
Sponsor:
Other
Protocol IDs:
SIOP-EUROPE-HR-NBL-1
, ESIOP, EU-20148, NCT00030719
23.
Phase III Partially Randomized Study of Neoadjuvant Chemotherapy Followed By Surgery and Adjuvant Chemotherapy in Children With Wilms' Tumor
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and under
Sponsor:
Other
Protocol IDs:
SIOP-WT-2001
, SFOP-SIOP-WT-2001, CCLG-SIOP-WT-2001, GPOH-GERMANY-SIOP-WT-2001, EU-20208, NCT00047138
24.
Phase III Randomized Study of Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone (BEACOPP) Versus Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) in Patients With Stage III or IV Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
16 to 60
Sponsor:
Other
Protocol IDs:
EORTC-20012
, GELA-EORTC-20012, BNLI-EORTC-20012, GELCAB-EORTC-20012, NORDICLG-EORTC-20012, CAN-NCIC-EORTC-20012, ALLG-HD04, hd8, NCT00049595
25.
Phase III Study of Surgery Followed By Compressed Cisplatin, Etoposide, and Bleomycin in Children With Newly Diagnosed Low- or Intermediate-Risk Extracranial Germ Cell Tumors
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 21 at diagnosis
Sponsor:
NCI
Protocol IDs:
COG-AGCT0132
, NCT00053352, AGCT0132
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
